These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3083619)

  • 1. [Safety and sensitizing properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine and its effect on hematological indices].
    Kharitonova AM; Grigor'eva LV; Antsiferova NG; Radkevich SA; Vetkova LG
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Feb; (2):14-9. PubMed ID: 3083619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Production and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. IV. The effect of immunization with Pseudomonas aeruginosa vaccine on the immune status of volunteer donors].
    Titova TI; Sidorova TN; Radkevich SA; Antsiferova NG; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Aug; (8):80-4. PubMed ID: 3933225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cell-free Pseudomonas vaccine: its immunochemical characteristics and immunogenicity].
    Bandman OA; Edvabnaia LS; Bulk VF; Zhvanetskaia MI; Mashilova GM
    Zh Mikrobiol Epidemiol Immunobiol; 1987 Nov; (11):44-7. PubMed ID: 3124416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine].
    Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunological activity and toxicity of a peroral vaccine made from mutant Re Salmonella minnesota].
    Apollonin AV; Artemova EK; Vlasov GS; Kuklina SI; Salov VF
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Mar; (3):78-82. PubMed ID: 6730810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Isolation and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. An evaluation of the biological properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine].
    Ttitova TI; Grigor'ev NI; Antsiferova NG; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Jul; (7):14-8. PubMed ID: 3931392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protective effect of a corpuscular polyvalent Pseudomonas aeruginosa vaccine in generalized chronic Pseudomonas aeruginosa infection in mice with cyclophosphamide-induced leukopenia].
    Vetkova LG; Zaĭtsev LG; Khasman EL; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Mar; (3):14-8. PubMed ID: 3085409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.
    Hatano K; Boisot S; DesJardins D; Wright DC; Brisker J; Pier GB
    Infect Immun; 1994 Sep; 62(9):3608-16. PubMed ID: 7520416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of a corpuscular polyvalent Pseudomonas aeruginosa vaccine on the proliferation and differentiation of hematopoietic stem cells and erythropoiesis].
    Khorobrykh VV; Vetkova LG; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Jan; (1):65-9. PubMed ID: 3085406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
    Cryz SJ; Sadoff JC; Cross AS; Fürer E
    Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836
    [No Abstract]   [Full Text] [Related]  

  • 11. [Protective action of a corpuscular polyvalent Pseudomonas aeruginosa vaccine against representative enterobacteria].
    Vetkova LG; Antsiferova NG; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Apr; (4):26-30. PubMed ID: 2409719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimentally determined safety and immunological activity of vaccine based on antigens isolated from Pseudomonas aeruginosa in medium K-4].
    Nuriddinova NR; Sheremet'ev NN; Ivanova LE; Garib FIu; Iskhakova KhI
    Zh Mikrobiol Epidemiol Immunobiol; 2005; (3):57-60. PubMed ID: 16028515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines against Pseudomonas aeruginosa infection: 1. Experimental studies.
    Stanislavsky ES; Joo I; Mashilova GM; Boolk VF; Boltutsy LG; Zakgeim DA; Severtśova MK; Yedvabnaya LS; Gladus MA; Fatkhinurova TI
    Vaccine; 1985 Jun; 3(2):128-36. PubMed ID: 3929491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine].
    Moroz AF; Radkevich SA; Antsiferova NG; Brodinova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):44-9. PubMed ID: 6171956
    [No Abstract]   [Full Text] [Related]  

  • 15. The epidemiology of Pseudomonas aeruginosa and the development of a polyvalent vaccine.
    Pranter W; Staerk J; Zellner R; Zwisler O
    Prog Immunobiol Stand; 1971; 5():414-8. PubMed ID: 4633968
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effectiveness of a polyvalent corpuscular Pseudomonas aeruginosa vaccine, antibiotics and their combinations in experimental chronic Pseudomonas aeruginosa infection].
    Vetkova LG; Antsiferova NG; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Mar; (3):51-6. PubMed ID: 3922187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental studies on the protective efficacy of a Pseudomonas aeruginosa vaccine.
    Stanislavsky ES; Edvabnaya LS; Bandman OA; Boolk VF; Zhvanetskaya MI; Vargina AK
    Vaccine; 1989 Dec; 7(6):562-6. PubMed ID: 2514518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
    Moroz AF; Kharitonova AM; Chanturiia TsK
    Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined Staphylococcus-Proteus-Pseudomonas vaccine. II. The toxicity of the vaccine in "chronic" experiments and its ability to protect animals against Proteus and Staphylococcus infections].
    Kreĭnin LS; Egorova NB; Stanislavskiĭ ES; Kaverina KG; Levina LA
    Zh Mikrobiol Epidemiol Immunobiol; 1983 May; (5):87-92. PubMed ID: 6410625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new polyvalent Pseudomonas vaccine.
    Miler JM; Spilsbury JF; Jones RJ; Roe EA; Lowbury EJ
    J Med Microbiol; 1977 Feb; 10(1):19-27. PubMed ID: 402473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.